Form 4: Anterix CEO Scott Lang Acquires 191,326 Stock Options
SEC Form 4 Filing
Anterix CEO Scott Lang was granted 191,326 stock options on January 17, 2025, which vest over three years.
Summary
- Anterix CEO Scott Lang was granted 191,326 stock options on January 17, 2025.
- The options have an exercise price of $30.99.
- The options vest in three annual installments starting on January 17, 2025, contingent on Lang's continued service to the company.
- The options expire on January 17, 2026.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Risks
- The value of the options is dependent on the future performance of Anterix stock.
- If the stock price does not exceed the exercise price of $30.99, the options will have no value.
Future Outlook
The vesting of the stock options is contingent on the CEO's continued service to the company, suggesting a focus on long-term leadership stability.
Industry Context
Stock option grants are a common form of executive compensation in publicly traded companies, designed to incentivize performance and align management's interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation across various industries.
- The vesting schedule of three years is also a common practice to ensure long-term commitment from executives.
- The specific terms of the grant, such as the exercise price and vesting schedule, are typical for a company of Anterix's size and stage.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see this as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 01/17/2025 | Date of the stock option grant and the start of the vesting period. |
| 01/17/2026 | Expiration date of the stock options. |
| 01/22/2025 | Date the form was signed by Gena L. Ashe, Attorney-in-Fact. |
Keywords
stock options, executive compensation, insider trading, Anterix, ATEX, Scott Lang
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.